Skip to main content

Actelion Value Stock - Dividend - Research Selection

Actelion

ISIN: CH0010532478, WKN: 936767

Market price date: 30.11.-0001
Market price: 0,00 CHF




Actelion Fundamental data and company key figures of the share

Annual reports in CHF
Key figures 05-04-2017
Cash flow
Net operating cash flow 919.530.000
Capital Expenditures -57.000.000
Free cash flow 862.529.984
Balance sheet
Total Equity 1.325.500.000
Liabilities & Shareholders equity 2.106.480.000
Income statement
Net income 696.386.000
Eps (diluted) 6,460
Diluted shares outstanding 107.811.000
Net sales/revenue 2.417.940.000

Fundamental ratios calculated on: 30-11--0001

Ratios
Key figures 30-11--0001
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI0,00
ROE0,00
Income statement
P/E0,00
Div. Yield0,00%
P/B0,00
P/S0,00


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolALIOF
Market Capitalization30.431.592.448,00 USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internetwww.actelion.de


Description of the company

Actelion Ltd is a Switzerland-based biopharmaceutical company that focuses on the discovery, development and commercialization of drugs for diseases with unmet medical needs. The Company specializes in the field of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. Its portfolio of PAH treatments includes Opsumit (macitentan), Tracleer (bosentan), Uptravi (selexipag), Veletri (epoprostenol for injection) and Ventavis (iloprost). Opsumit is an orally available endothelin receptor antagonist (ERA). Tracleer is an orally available endothelin receptor antagonist (ERA). Uptravi is an oral, selective IP receptor agonist targeting the prostacyclin pathway in PAH. Veletri (epoprostenol for injection) is an intravenous prostacyclin. Ventavis is an inhaled formulation of iloprost, a synthetic compound similar to prostacyclin (PGI2).

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.actelion.de